M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
